论文部分内容阅读
目的:评价西替伪麻缓释片治疗季节性或常年性过敏性鼻炎疗效和安全性。方法:按照随机、双盲、双模拟盐酸西替利嗪对照设计,将210例受试者按1∶1随机分配至西替伪麻缓释片组和盐酸西替利嗪胶囊组,进行系统性的临床试验研究。结果:服药7 d时的鼻塞、流涕、鼻痒程度评分改善,疾病总体严重程度和总体改善的评价分析中,试验组较对照组改善的更好,差别有统计学意义。与对照组相比不良事件发生率差别无统计意义。无严重不良事件发生。结论:西替伪麻缓释片是一种安全、有效的治疗季节性或常年性过敏性鼻炎的药物,值得推广使用。
Objective: To evaluate the efficacy and safety of cetuximab in the treatment of seasonal or perennial allergic rhinitis. METHODS: According to a randomized, double-blind, double-simulated cetirizine hydrochloride control design, 210 subjects were randomized to receive cilostazol and cetirizine hydrochloride capsules at a 1: 1 ratio. Systemic Sexual clinical trials. Results: In the evaluation and analysis of nasal congestion, runny nose, nasal pruritus score on the seventh day after medication, the overall severity of the disease and overall improvement were better in the experimental group than in the control group, and the difference was statistically significant. Compared with the control group, the incidence of adverse events was not statistically different. No serious adverse events occurred. Conclusion: Xidi Pseudoephedrine Sustained Release Tablets is a safe and effective drug for the treatment of seasonal or perennial allergic rhinitis, which is worth promoting.